期刊文献+

2型糖尿病老年女性与肥胖、糖脂代谢关系 被引量:1

原文传递
导出
摘要 测60例患T2DM老年女性病例组和40例正常对照组的BMI和WHR及血脂血糖;双能X线吸收仪DEXA精确的测量身体脂肪的分布。结果:1、T2DM组的体重、血压、BMI、WHR、TC、TG、LDL-C、水平高于对照组;前组的Lp(a)、HDL-C则低于后组,差别有统计学意义(P<0.05)。2、肥胖组(WHR>0.85)的TG、2hPG、ApoB均值大于非肥胖组(WHR≤0.85);前组的HDL-C、Lp(a)均值小于后组(P<0.05)。3、WHR与LDL-C、TC、ApoB、TG、2hPG呈显著正相关,而与HDL-C呈显著负相关(P<0.05);BMI仅与TG、2hPG呈正相关(P<0.05)。4、T2DM组与对照组比较,前者的上半身脂肪量、体脂肪率、上下半身脂肪率比均高于后者,下半身脂肪率却明显低,两组差别有显著性统计意义(P<0.05)。结论:高脂血症老年女性患者的身体脂肪分布呈现上半身型,且易发生糖尿病;2型糖尿病老年女性患者糖代谢紊乱与脂代谢紊乱及肥胖有密切关系。
作者 毕婉蓉 季静
出处 《实用糖尿病杂志》 2007年第1期25-27,共3页 Journal of Practical Diabetology
  • 相关文献

参考文献7

  • 1Viner RM,Segal TY,Lichtarowicz-Krynska E,et al.Prevalence of the insulin resistance syndrome in obesity.Archives Of Disease In Childhood 2005; 90 (1):10-14.
  • 2Wilber JF.Neuropeptides,appetite regulation and human obesity.JAMA 2003; 266:257.
  • 3Diamant M,Heine RJ.Thiazolidiones in type 2 diabetes mellitus:Current clinical evidence.Drug 2003; 61 (13):1373-1405.
  • 4Sarlund H,Pyorala K,PenttilaM,et al.Early abnormalities in coronary heart disease risk factors in relatives of subjects with non-insulin-dependent diabetes.Arterioscler Thromb 2002; 12:657.
  • 5Marchesini C,Brizi M,Bianchi G,et al.Noralcoholic fatty liver disease:a feature of the metabolic syndrome.Diabeatis 2001; 50:1844-1850.
  • 6Velho G,Erich D,Turpin E,et al.Lipoprotein (a) in diabetic patients and normoglycemic relatives in familial NIDDM.Diabetes Care 2003; 16:742.
  • 7Edelman SV.The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors.Rev Cardiovase Med 2003; 4 (suppl 6):9-37.

同被引文献13

  • 1Daniel J Drucker,John B Buse,Kristin Taylor,David M Kendall,Michael Trautmann,Dongliang Zhuang,Lisa Porter.Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study[J]. The Lancet . 2008 (9645)
  • 2John B Buse,Julio Rosenstock,Giorgio Sesti,Wolfgang E Schmidt,Eduard Montanya,Jason H Brett,Marcin Zychma,Lawrence Blonde.Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)[J]. The Lancet . 2009 (9683)
  • 3?. Erdogdu,D. Nathanson,?. Sj?holm,T. Nystr?m,Q. Zhang.Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor[J]. Molecular and Cellular Endocrinology . 2010 (1)
  • 4Dario Giugliano,Eberhard Standl,Tina Vilsb?ll,John Betteridge,Riccardo Bonadonna,Ian W. Campbell,Gerit-Holger Schernthaner,Bart Staels,Antonia Trichopoulou,Eduardo Farinaro.Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?[J]. Acta Diabetologica . 2009 (3)
  • 5Yan Gao,Kun Ho Yoon,Lee-Ming Chuang,Viswanathan Mohan,Guang Ning,Sanjiv Shah,Hak Chul Jang,Ta-Jen Wu,Don Johns,Justin Northrup,Robert Brodows.Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea[J]. Diabetes Research and Clinical Practice . 2008 (1)
  • 6Marzieh Salehi,Benedikt A. Aulinger,David A. D’Alessio.Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins[J]. Endocrine Reviews . 2008 (3)
  • 7JF Gautier,S Fetita,E Sobngwi,C Salaün-Martin.Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes[J]. Diabetes and Metabolism . 2005 (3)
  • 8Yoder Stephanie M,Yang Qing,Kindel Tammy L,Tso Patrick.Differential responses of the incretin hormones GIP and GLP-1 to increasing doses of dietary carbohydrate but not dietary protein in lean rats. American journal of physiology. Gastrointestinal and liver physiology . 2010
  • 9施广德,张晓兰,黄文龙.艾塞那肽对2型糖尿病患者的疗效观察[J].中国糖尿病杂志,2011,19(10):770-772. 被引量:5
  • 10付鸿玉,刘冰梅,刘立波.艾塞那肽治疗2型糖尿病20例临床观察[J].中国医疗前沿,2011,6(18):32-32. 被引量:6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部